INVA Innoviva, Inc.
$21.12▲ +0.86%
Healthcare
Other
Volume 585.3K
Avg Volume (10D) 602.1K
Key Metrics & Fundamentals
Market Cap
$1.53B
P/E Ratio
4.9
Div Yield
0.00%
52W Range
17.45 - 25.15
% vs 50 MA
0.62%
% vs 200 MA
-3.43%
RSI-14
52.3
MACD Histogram
+0.0100
Beta (1Y vs SPY)
0.00
Free Cash Flow
$51.54M
Gross Rev
$119.59M
Gross Profit
$90.62M
EBITDA
-$66.77M
COGS
$28.98M
Operating Exp
$39.76M
Operating Income
$50.86M
EBIT
$50.86M
Pretax Income
-$108.02M
Net Income
-$83.42M
EPS (Diluted)
-1.14
Price & Volume History
Loading chart…
Recent News
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
Business Wire · Oct 19, 2026 8:00 AM ET
Do Options Traders Know Something About Innoviva Stock We Don't?
Zacks · Oct 12, 2026 10:11 AM ET
Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal?
Simply Wall St. · Oct 8, 2026 3:19 PM ET
INVA vs. MRK: Which Stock Is the Better Value Option?
Zacks · Oct 8, 2026 10:40 AM ET
5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential
Zacks · Oct 8, 2026 8:54 AM ET
Should Value Investors Buy Innoviva (INVA) Stock?
Zacks · Oct 8, 2026 8:40 AM ET
Oppenheimer Sees Massive Upside in 2 Stocks
GuruFocus.com · Sep 30, 2026 2:10 PM ET
Innoviva to Participate in Upcoming Investor Conferences
Business Wire · Sep 2, 2026 8:00 AM ET
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
Business Wire · Aug 11, 2026 4:05 PM ET
How Innoviva’s Q2 Loss and Aggressive Buybacks Could Reshape Capital Allocation for INVA Investors
Simply Wall St. · Aug 7, 2026 7:12 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See INVA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.